PROTEOMIC CHANGES IN MUSCLE CELLS WITH PULMONARY HYPERTENSION

肺动脉高压时肌肉细胞的蛋白质组变化

• 批准号: 8365578
• 负责人: Peter Rudolph Polgar
• 金额: $ 0.46万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-06-01 至 2012-08-09
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8365578
• 关键词: Affect; Animal Model; Biochemical; Biology; Disease; Fatal Outcome; Funding; Grant; Individual; Investigation; Knowledge; Mass Spectrum Analysis; Medicine; Muscle Cells; National Center for Research Resources; Pathway interactions; Principal Investigator; Proteomics; Pulmonary Hypertension; Research; Research Infrastructure; Resources; Source; Tissues; United States National Institutes of Health; cost; pulmonary arterial hypertension

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Pulmonary arterial hypertension (PAH) is a devastating disease with a usually fatal outcome There is as yet no reliable treatment for PAH, largely because the biochemical cause and course remain unknown.There are no adequate animal models. We are undertaking proteomics investigations of tissues from affected individuals, in order to gain knowledge about the pathways that are affected in conjunction with the disease.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 肺动脉高压 (PAH) 是一种毁灭性的疾病，通常会致命。目前还没有可靠的治疗方法，主要是因为其生化原因和病程仍然未知。没有足够的动物模型。我们正在对受影响个体的组织进行蛋白质组学研究，以便了解与该疾病相关的受影响途径。